Dexcom Inc. (DXCM) has been experiencing a series of activity in recent times. The company recorded fluctuations in its share price, swinging between gains and losses. This comes after an increase in its holdings by the Neuberger Berman Group and other asset management firms like Aristotle Growth Equity Fund and TD Asset Management, among others. Various entities, such as Fisher Asset Management and Blair William & Co have also reduced their holdings.
The company recently expanded its leadership team with the return of Kevin Sayer as executive chairman and the addition of Google's Rick Osterloh to its board. Still, numerous firms are forecasting a bullish outcome for the firm like Mizuho raising its price target to $90.
Dexcom's Q4 results beat estimates, and its growth outlook for 2026 was reported to look promising. Dexcom has enhanced its board, bolstering innovation and demonstrating leadership in glucose sensors.
However, recent lawsuits concerning the safety and reliability of its devices, and Barclays' downgrade due to anticipated competition in core segments, could affect its valuation. Argus initiated coverage on Dexcom with a buy rating, offering a more optimistic perspective on the company's performance.
Dexcom DXCM News Analytics from Fri, 29 Aug 2025 07:00:00 GMT to Sat, 07 Mar 2026 11:58:24 GMT - Rating 2 - Innovation 5 - Information 8 - Rumor 0
